Diltiazem Hydrochloride Tablets

This product is a calcium channel blocker, and its action is related to the inhibition of calcium ion influx during myocardial and vascular smooth muscle depolarization. This product can effectively dilate the epicardial and subendocardial coronary arteries, relieve spontaneous angina pectoris or angina pectoris caused by coronary artery spasm induced by ergonovine; by slowing down the heart rate and lowering blood pressure, it reduces myocardial oxygen demand, increases exercise tolerance and relieves exertional angina pectoris. This product can relax vascular smooth muscle, reduce peripheral vascular resistance, and lower blood pressure; the extent of its blood pressure reduction is related to the degree of hypertension, and only slightly reduces blood pressure in people with normal blood pressure. This product has a negative inotropic effect and can slow down the conduction of the sinoatrial node and atrioventricular node.

The main ingredients and chemical names of this product are: cis-()-5-[(2-dimethylamino)ethyl]-2-(4-methoxyphenyl)-3-acetoxy-2,3-dihydro-1,5-phenylpropylthiazepine-4(5H)-one hydrochloride

This product is white tablets

1. Angina pectoris caused by coronary artery spasm and exertional angina pectoris. 2. Hypertension.

Oral administration: the initial dose is 60~120 mg/time, twice a day (2~4 tablets at a time, twice a day), and the average dose range is 240~360 mg/day.

Common adverse reactions: edema, headache, nausea, dizziness, rash, weakness. Rare adverse reactions (cardiovascular system: angina pectoris, arrhythmia, atrioventricular block, bradycardia, bundle branch block, congestive heart failure, abnormal electrocardiogram, hypotension, palpitations, syncope, tachycardia, ventricular premature beats. Nervous system: dreaminess, amnesia, depression, abnormal gait, hallucinations, insomnia, nervousness, paresthesia, personality changes, drowsiness, tremor. Digestive system: anorexia, constipation, diarrhea, taste disorder, indigestion, thirst, vomiting, weight gain, mild increase in alkaline phosphatase, lactate dehydrogenase, aspartate aminotransferase, and alanine aminotransferase. Skin: petechiae, photosensitivity, itching, urticaria.<

1. Patients with sick sinus syndrome without pacemaker. 2. Patients with II or III degree atrioventricular block without pacemaker. 3. Patients with systolic blood pressure lower than 12kPa (90mmHg). 4. Patients allergic to this product. 5. Patients with acute myocardial infarction or pulmonary congestion.

Precautions for children: The safety and effectiveness of this product in children have not been determined. Precautions for pregnancy and lactation: There is a lack of controlled trial data for its use in pregnant women, so pregnant women must weigh the pros and cons when using this product. This product can be excreted through breast milk, and its concentration is close to the blood drug concentration. If it is necessary for lactating women to use this product, the feeding method of the baby must be changed. Precautions for the elderly: No clinical data on the use of this drug in the elderly have been found, but it is recommended that elderly patients can start taking the drug at half the normal dose.

1. β-blockers: Studies have shown that the combination of diltiazem hydrochloride and β-blockers is well tolerated, but there is insufficient data in patients with left ventricular dysfunction and conduction dysfunction. This product can increase the bioavailability of propranolol by nearly 50%, so the dose of propranolol needs to be adjusted when starting or stopping the combination of the two drugs. 2. Cimetidine: Due to the inhibition of cytochrome P450 oxidase, the first-pass metabolism of this product is affected, which can significantly increase the peak blood concentration and the area under the drug-time curve of this product. Ranitidine only slightly increases the blood concentration of this product. 3. Digoxin: There are reports that this product can increase the blood concentration of digoxin by 20%, but there are also reports that it has no effect. Although the results are contradictory, the blood concentration of digoxin should be monitored when starting, adjusting and stopping treatment with this product to

Keep in a light-proof and airtight container.

30mg

36 months

Shandong LINUO Pharmaceutical Company Limited

• Founded in:

  2002-05-14

• Address:

  No. 30766, Jingshi East Road, Jinan City

• Tax NO.:

  91370100739258448G

• Registered Funds:

  300 million yuan

• Website:

  Log in to view

• Email:

  Log in to view